Biotech entity
Centers for Medicare & Medicaid Services (CMS) is most often covered alongside Biden Administration, which appears in 2 of these 4 stories. Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Centers for Medicare & Medicaid Services (CMS) is most often covered alongside Biden Administration, which appears in 2 of these 4 stories. Coverage clusters in pharma, which accounts for 3 of those 4, with the remainder spread across 1 other category. The 8-day window averages about 3.5 stories each week. Each story carries 2.8 original sources on average, compared with 2.4 for the broader beat in this window. The 6.5 average consequence score is above the beat benchmark of 5.7 in the same window. This profile follows 4 Biotech stories mentioning Centers for Medicare & Medicaid Services (CMS) across the period from July 29, 2026 to August 5, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 59 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Centers for Medicare & Medicaid Services (CMS). Shared-story counts are live from our verified record — not editorial picks.
Subsidy Program Ends
The temporary premium subsidy officially concludes; beneficiaries may face higher monthly costs unless insurers absorb the cost or new policies emerge.
2027 Premiums Announced Amid Elections
Part D plan rates for 2027 are released in the fall, coinciding with November midterm elections where cost of living is a top issue.
CMS Announces Subsidy Program Will End
Administrator Dr. Mehmet Oz announces the subsidy will conclude in 2027, citing $3.6B in taxpayer costs for 2026 and a desire to stop subsidizing insurers.
Drug Price Cuts Take Effect
Lower negotiated prices for 10 popular and expensive drugs begin for Part D enrollees, as mandated by the IRA.
Biden Administration Implements Temporary Part D Subsidy
A subsidy program is launched to offset premium increases for Medicare Part D enrollees caused by the IRA’s benefit changes.
Inflation Reduction Act Signed
Legislation includes drug price negotiation and Part D benefit redesign, setting the stage for higher base premiums that later necessitate a temporary subsidy.
CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Source: rttnews.com · finanznachrichten.de
The elimination of a $3.6 billion Medicare Part D subsidy may raise drug costs for seniors, potentially reducing adherence and impacting pharmaceutical manufacturers' market outlook. The move adds to pricing pressures from the Inflation Reduction Act.
Source: nbcbayarea.com · nbcnewyork.com
Termination of the temporary Medicare Part D subsidy by the Trump administration could shift $3.6 billion in costs, affecting drug pricing dynamics and patient adherence, with implications for pharma and biotech companies reliant on senior populations.
Source: orlandosentinel.com · citizensvoice.com
The termination of the $3.6 billion Part D premium subsidy could alter prescription utilization patterns for 25 million Medicare beneficiaries, potentially reducing demand for branded drugs and pressuring pharma companies reliant on Part D volume.
Source: kprcradio.iheart.com · channel963.iheart.com
Centers for Medicare & Medicaid Services (CMS) is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
